SEHK:9966Biotechs
Alphamab Oncology (SEHK:9966) TTM Loss Of C¥113.9m Tests Bullish Profitability Narratives
Alphamab Oncology FY 2025 results in focus
Alphamab Oncology (SEHK:9966) has posted its FY 2025 numbers with first half revenue of C$319.4 million and basic EPS of C$0.02, providing an indication of how the rest of the year may shape up for margins. The company has seen revenue move from C$173.6 million in 1H 2024 to C$466.5 million in 2H 2024 and then to C$319.4 million in 1H 2025, while EPS shifted from a loss of C$0.05 in 1H 2024 to C$0.22 in 2H 2024 and C$0.02 in the latest period. This...